Corcept Therapeutics Incorporat

Valuation Analysis

About the Company

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relac

Corcept Therapeutics Incorporat Stock at a Glance

Corcept Therapeutics Incorporat (CORT) is currently trading at $82.91 with a market capitalization of $8.9B. The trailing P/E ratio stands at 236.89x, with a forward P/E of 33.23x. The 52-week range spans from $28.66 to $91.00; the current price is 8.9% below the yearly high. Year-over-year revenue growth stands at +4.9%. The net profit margin stands at 6.16%.

💰 Dividend

Corcept Therapeutics Incorporat currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

5 analysts rate Corcept Therapeutics Incorporat (CORT) on consensus: Strong Buy. The average price target is $88.00, implying +6.14% from the current price. Analyst price targets range from $50.00 to $135.00.

Corcept Therapeutics Incorporat: The Investment Case in Detail

Corcept Therapeutics Incorporat (CORT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 98.25%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

The Bear Case

Revenue growth has slowed to just 4.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Short interest sits at 10.57% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.81, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 33.23x is meaningfully below the trailing 236.89x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (10.57%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Corcept Therapeutics Incorporat?

Compare top-rated brokers — low fees, trusted providers, fully regulated.